ClinicalTrials.gg
RecruitingNCT06331208LUNG-HFUpdated Aug 27, 2024

Mechanisms of Pulmonary Vascular Dysfunction in Heart Failure

An observational study in Heart Failure, Pulmonary Hypertension and Pulmonary Vascular Resistance Abnormality, sponsored by Institute for Clinical and Experimental Medicine. Recruiting at 1 site in Czechia. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2024-08-27.

Sponsored by Institute for Clinical and Experimental Medicine · Observational

How we know

From the registry’s dates

  • Started Aug 2024; still recruiting 2 years 2 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
230
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 166 studies in Heart Failure with a site in Czechia — 36 open to participants now, 45 under way, 14 of them phase 3. Heart Failure · Czechia.

Planned enrollment
18th of 30
230 · median 418
Started
2024
with 15 others
Observational
30 of 166
10 open now
Primary completion
2026-12
later than 12 of 44 live
Registered
139th of 166
by date
Lead sponsor
5 of 166
Institute for Clinical and Experimental Medicine

Among the 166 studies in Heart Failure with a site in Czechia, this one is the 18th largest by planned enrollment of the 30 observational ones that give a count, is one of 16 that started in 2024, is one of 30 observational ones, reaches primary completion later than 12 of the 44 other live ones, and was the 139th registered.

Heart Failure

6,340 studies on the registry are indexed under Heart Failure; 1,397 are open to participants now.

Browse Heart Failure studies →

Open to participants now

36 of the 166 studies in Heart Failure with a site in Czechia are open now. Recruiting first, the newest first:

31 more — sign in →

All 36 open studies →

A study can be open while its sites in Czechia have not opened yet or have stopped. Only those recruiting at a site in Czechia →

Who these studies take

Of the 968 Heart Failure studies recruiting now, 691 (71%) set no upper age limit and 90 (9%) stop at 75 or younger; 64 take children under 18; 97 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 166 studies in Heart Failure with a site in Czechia, or all of them as a file.
02

Study summary

Heart failure (HF) patients often develop pulmonary hypertension (PH) that leads to transition into a biventricular HF with poor prognosis.

There are two PH components: 1) passive transmission of increased left atrial pressure, 2) heart failure (HF) related pulmonary vascular dysfunction (PVD) with increased vascular resistance. Intriguingly, only some, but not all HF patients develop heart failure-related PVD. The mechanisms and non-invasive detection of HF-PVD are poorly understood and are the focus of the current grant application. Development of PVD is linked to insufficiently characterized metabolic factors that may be mediators of HF-PVD.

Untargeted metabolomics is an emerging powerful platform for the discovery of pathways linked to diseases. Its specificity can be further enhanced using transpulmonary gradient sampling.

Part A of the project aims to identify novel metabolites associated with the presence of PVD in patients with HF that can serve as biomarkers or targets and will provide biologic insights into PVD. Part C will assess the effects of reverting of metabolic alterations (identified in part A) by a drug/diet on pulmonary vasculature in experimental HF-related PVD. The "gold standard" for the detection of PVD is right heart catheterization, which is invasive and risky. Heart failure-related PVD is therefore often diagnosed late.

There is a need for noninvasive tests that may help to detect PVD in early stages and can be done repeatedly. Recent advances in artificial intelligence (AI)-assisted automated quantitative analysis of lung texture from low-dose contrast-free high-resolution CT images allow to quantify lung water content, interstitial changes or vessel volume, and may provide clues for detection of heart failure-related PVD. Such an approach, not tested yet, will be utilized for the detection of HF-PVD (part B). Clinical and functional characteristics of lung circulation (exercise hemodynamics, diffusion capacity, perfusion) will be analyzed in relation to quantitative CT data.

Read the detailed description

Goals of the project are:

A) To identify metabolic factors associated with the development of heart failure related pulmonary vascular disease (PVD) using unbiased metabolomic analysis of blood samples obtained before and after passage through lungs (transpulmonary metabolome), obtained during medically indicated right heart catheterization of HF patients with variable degree of pulmonary vasculopathy. Findings from discovery cohort A1 (200 HF, 30 controls) will be prospectively validated in validation cohort A2 (200 HF, 30 controls). Clinical data (medication, comorbidities, nutritional intake) will be analyzed to identify explanatory links to transpulmonary metabolome and increased pulmonary vascular resistance. The goal is to discover metabolic factors and pathways critical for PVD development, that might be targeted by pharmaco-intervention.

B) To identify structural and functional characteristics of heart failure (HF) related PVD using advanced imaging (cohort B, 60 HF patients, 30 controls). Advanced non-invasive imaging methods (high resolution non-contrast CT, SPECT) will be used to identify early changes in lung structure indicating the presence of pulmonary vascular disease. HF subjects with variable elevation of pulmonary vascular resistance will be extensively phenotyped using novel automated AI-augmented analysis of CT data texture, and by SPECT perfusion imaging. These morphologic characteristics will be linked to functional parameters (diffusion capacity, pulmonary vascular resistance change during exercise). The goal is to develop non-invasive imaging markers of early PVD due to HF.

C) To test the impact of the correction of metabolic abnormalities on heart failure-related PVD in animal model. Animal model mimicking PVD due to HF will be characterized and the impact of the dietary or pharmacological intervention (based on findings from part A) on pulmonary hemodynamics will be tested in rats with myocardial infarction by left anterior descending (LAD) artery ligation combined with low-dose toxin to pulmonary circulation (monocrotaline or substance Sugen 5416).

03

Conditions studied

  • Heart Failure
  • Pulmonary Hypertension
  • Pulmonary Vascular Resistance Abnormality

Keywords

  • heart failure
  • pulmonary Hypertension
  • pulmonary Vasculopathy
  • Type 2 pulmonary Hypertension
  • right heart catheterisation
  • metabolomics
  • computed tomography of the lungs
  • AI-assisted quantitative lung CT
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

HF:

Patients with HFrEF reffered to Institute for Clinical and Experimental Medicine, Prague (IKEM) for diagnostic evaluation

Controls non-HF controls reffered to IKEM for diagnostic or therapeutic procedure

Eligibility criteria

A) Inclusion Criteria

HF group:

  • age>18y
  • signed ,
  • left ventricular (LV) \<50%
  • duration of HF>6 months,
  • loop diuretic use,
  • clinical indication to right heart catheterisation

Control group:

  • Age >18years
  • Signed informed consent
  • Non-HF subjects referred to Institute for Clinical and Experimental Medicine (IKEM) in Prague for an invasive procedure (PFO closure, arrhythmia ablation, for subjects undergoing RHC) or non-invasive diagnostic evaluation (controls without invasive sampling)

B) Exclusion Criteria:

Heart Failure group:

  • Patients with hemodynamic instability requiring inotropic support
  • Severe renal insufficiency (estimated \<0.6 ml/s)
  • Acute coronary syndrome
  • High cardiac output (cardiac index >4 l/m2)
  • Known pulmonary hypertension of other type than II (type I, III, IV)
  • Active infection
  • Respiration insufficiency
  • Large pleural effusion
  • Severe intrinsic lung disease (treated (COPD)

    • asthma, known interstitial lung disease)

Control group:

  • Pulmonary hypertension (RV systolic pressure estimate on screening > 45 mmHg)
  • History of recent pulmonary embolism \< 1 year
  • Echocardiographic evidence of reduced function of right or left ventricle
  • Treated asthma/COPD, known intersticial lung disease
  • Significant exercise intolerance ( > II)
Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

LVEF (left ventricular ejection fraction)

The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

COPD

Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
230 participants (estimated)
Patient registry
No
Biospecimen retention
Samples with dna

Groups and cohorts

  • controls

    Subjects without heart failure or pulmonary hypertension undergoing clinically indicated diagnostic evaluation or therapeutic procedure

    Diagnostic Test: non-contrast chest CT · Diagnostic Test: spirometry with diffusing lung capacity for carbon monoxide (DLCO) analysis · Diagnostic Test: Omics analysis of blood plasma obtained from pulmonary artery or peripheral blood

  • heart failure

    Subjects with chronic heart failure due to reduced ejection fraction (EF), undergoing clinically indicated right heart catheterisation (evaluation for left ventricular assist device (LVAD)/transplantation (TX) or other decision)

    Diagnostic Test: non-contrast chest CT · Diagnostic Test: spirometry with diffusing lung capacity for carbon monoxide (DLCO) analysis · Diagnostic Test: Omics analysis of blood plasma obtained from pulmonary artery or peripheral blood · Diagnostic Test: supine bike exercise during right heart catheterisation · Diagnostic Test: Lung ventilation/perfusion SPECT

Interventions

  • Diagnostic testnon-contrast chest CT

    patients who undergo clinically indicated evaluation of pulmonary circulation (right heart catheterisation - RHC) will undergo non-contrast CT of the chest, blood sampling from pulmonary artery and spirometry with DLCO analysis.

  • Diagnostic testspirometry with diffusing lung capacity for carbon monoxide (DLCO) analysis

    patients who undergo clinically indicated evaluation of pulmonary circulation (RHC) will undergo non-contrast CT of the chest, blood sampling from pulmonary artery and spirometry with DLCO analysis.

  • Diagnostic testOmics analysis of blood plasma obtained from pulmonary artery or peripheral blood

    patients who undergo clinically indicated evaluation of pulmonary circulation (RHC) will undergo non-contrast CT of the chest, blood sampling from pulmonary artery and spirometry with DLCO analysis.

  • Diagnostic testsupine bike exercise during right heart catheterisation

    subgroup of HF subjects who undergo right heart catheterisation will perform short supine bike exercise during RHC

  • Diagnostic testLung ventilation/perfusion SPECT

    subgroup of HF subjects will undergo ventilation/perfusion SPECT

06

What researchers measure

Primary outcomes

  1. biomarker of pulmonary vasculopathy in HF

    putative biomarker (protein or metabolite) identified by omics analysis of from plasma of HF patients (with low and high pulmonary vascular resistance) or controls

    Time frame: after recruitment and cross-sectional analysis of all enrolled subjects (no later than december 2026-the end of study)

  2. CT characteristics of pulmonary vasculopathy in HF

    average volume of pulmonary arterioles and venules by non-contrast high resolution CT

    Time frame: after recruitment and cross-sectional analysis of all enrolled subjects (no later than december 2026-the end of study)

  3. CT characteristics of presence of heart failure

    radiographic density of lung parenchyma (lung water estimation) by non-contrast high resolution CT

    Time frame: after recruitment and cross-sectional analysis of all enrolled subjects (no later than december 2026-the end of study)

07

Study locations

1 of 1 sites recruiting
08

References and documents

Individual participant data

Plan to share: Undecided

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Aug 2024 (actual). Primary completion is estimated for Dec 2026, 28 months after the start.

Of 799 non-industry observational studies under Heart Failure, half reached primary completion within 45 months of starting (the median), counting those still running; a quarter within 23 and three quarters within 100. This study's planned 28 months is below that.

Counting every sponsor, half of 982 studies reached it within 41 months; a quarter within 23 and three quarters within 89.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 23, 2024
First posted
Mar 26, 2024
StartActual
Aug 23, 2024
Primary completionEst.
Dec 30, 2026
CompletionEst.
Dec 30, 2026
Last update
Aug 27, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 27, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06331208
Lead sponsor
Institute for Clinical and Experimental Medicine
Responsible party
Vojtech Melenovsky, MD, PhD (Prof, MD, PhD, Institute for Clinical and Experimental Medicine) — Principal investigator
First posted
Mar 26, 2024
Start date
Aug 23, 2024
Primary completion
Dec 30, 2026 (estimated)
Completion
Dec 30, 2026 (estimated)
Last update
Aug 27, 2024

Study contacts

Vojtech Melenovsky, MD, PhD
Contact
vome@ikem.cz
420 236055190
Vojtech Melenovsky
principal investigator · Institute for Clinical and Experimental Medicine

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion